Off-label dermatologic uses of IL-17 inhibitors

Off-label dermatologic uses of IL-17 inhibitors

IL-17 inhibitors, including secukinumab, brodalumab, and ixekizumab, have been U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. In addition to psoriasis, IL-17 has been implicated in the pathophysiology of other inflammatory skin conditions. This review aims to synthe...

Full description

Bibliographic Details
Main Authors: Kevin K. Wu, Harry Dao
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Journal of Dermatological Treatment
Subjects:
secukinumab
ixekizumab
brodalumab
interleukin 17
il-17
hidradenitis suppurativa
acne inversa
pityriasis rubra pilaris
alopecia areata
contact dermatitis
lupus erythematosus
pyoderma gangrenosum
bullous pemphigoid
behçet’s disease
atopic dermatitis
Online Access:http://dx.doi.org/10.1080/09546634.2020.1737638

Internet

http://dx.doi.org/10.1080/09546634.2020.1737638

Similar Items